Background Anticoagulation in hospitalized COVID-19 patients has been associated with
survival benefit; however, the optimal anticoagulant strategy has not yet been defined. The …

Patients with coronavirus disease 2019 (COVID-19) have elevated D-dimer levels. Early
reports describe high venous thromboembolism (VTE) and disseminated intravascular …

Introduction: Thrombosis and bleeding are recognized complications of the novel
coronavirus infection (COVID-19), with a higher incidence described particularly in the …

Background Several observational studies have reported the rate of venous and arterial
thrombotic events in patients infected with COVID-19, with conflicting results. The aim of this …

The coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome
coronavirus (SARS-CoV-2) is our latest pandemic and has turned out to be a global public …

Abstract The Corona Virus Disease-2019 (COVID-19) pandemic is associated with a very
high incidence of thrombotic complications. The exact mechanisms for this excess risk for …

Background Coagulopathy is a common abnormality in patients with COVID‐19. However,
the exact incidence of venous thromboembolic event is unknown in anticoagulated, severe …

Patients with COVID-19 are at higher risk of thrombosis due to the inflammatory nature of
their disease. A higher-intensity approach to pharmacologic thromboprophylaxis may be …

Introduction COVID-19 may predispose to both venous and arterial thromboembolism due to
excessive inflammation, hypoxia, immobilisation and diffuse intravascular coagulation …

Abstract The 2019 coronavirus disease (COVID-19) presents with a large variety of clinical
manifestations ranging from asymptomatic carrier state to severe respiratory distress …